TOP TEN perturbations for NM_000076 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000076
Selected probe(set): 213348_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000076 (213348_at) across 5392 perturbations tested by GENEVESTIGATOR:

hepatocyte (ESC) / Hep-G2

Relative Expression (log2-ratio):8.087827
Number of Samples:8 / 9
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control Hep-G2
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code:

hepatocyte (ESC) / HepaRG

Relative Expression (log2-ratio):8.016643
Number of Samples:8 / 12
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)

Relative Expression (log2-ratio):5.342965
Number of Samples:3 / 11
Experimental HCC study 20 (CDX; Hep-G2; ectopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; ectopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.

small cell lung cancer study 4 (1. gen. PDX) / small cell lung cancer study 4 (XCL from PDX)

Relative Expression (log2-ratio):5.172452
Number of Samples:4 / 3
Experimental small cell lung cancer study 4 (1. gen. PDX)
A small cell lung cancer (SCLC) primary xenograft tumor tissue samples derived from three chemo-naive patients (LX22; LX33 and LX36; first generation-1. gen.). The discarded tissue obtained during bronchoscopy of SCLC patients was used to generate a xenograft. Aseptically resuspended tumour cells were injected s.c. in the flanks of nonobese diabetic/severe combined immunodeficient mice (NOD/SCID). The mice were sacrificed when the P0 tumors reached 1cm in diameter.
Control small cell lung cancer study 4 (XCL from PDX)
Xenograft-derived cell lines (XCL) established from a small cell lung carcinoma (SCLC) patient derived xenografts (PDX). The discarded tissue from three chemo-naive patients (LX22; LX33 and LX35) was obtained during bronchoscopy and used to generate a xenograft. Aseptically resuspended tumour cells were injected s.c. in the flanks of nonobese diabetic/severe combined immunodeficient mice. The mice were sacrificed when the P0 tumors reached 1cm in diameter. Obtained cells were used for conventional cell culture cultivation.

pancreatic islet study 3 (expanded; PPRF) / normal pancreatic islet sample

Relative Expression (log2-ratio):-4.9511347
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (expanded; PPRF)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded according to Pharmaceutical Production Research Facility Protocol (PPRF) for 6 weeks. Expansion phase: Approximately 2,500 islet equivalents were seeded onto 75-cm2 fibronectin-coated tissue culture-treated flasks in a proprietary serum-free medium (PPRF medium). The serum-free PPRF medium was supplemented with 30% serum-free mesenchymal-conditioned medium. When the cell migration resulted in the formation of large-size colonies, the cells were harvested by trypsinization and replated into new tissue culture flasks. Once the cells reached near confluence (80?90%) in monolayer, they were trypsinized, counted, and subcultured at a density of 5,000 cells per cm2. Thereafter, cells were serially passaged using the same protocol.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

rheumatoid arthritis study 37 (mono; CD14+ CD16+) / rheumatoid arthritis study 37 (mono; CD14+ CD16-)

Relative Expression (log2-ratio):4.7801437
Number of Samples:6 / 6
Experimental rheumatoid arthritis study 37 (mono; CD14+ CD16+)
Peripheral blood CD14+ CD16+ monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00?19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81?2.02 mg/dl; ESR 83.67?46.21 mm/hr; DAS28-CRP 5.06?1.22; DAS28-ESR 5.92?1.50; SDAI 28.76?19.03; CDAI 25.95?18.08; HAQ-DI 1.02?0.95; TJC28 8.17?6.4; SJC28 7.50?7.66; Pain, VAS 52.67?20.20; Physician GA, VAS 46.83 ?29.30 mm; Subject GA, VAS 56.00?17.61 mm
Control rheumatoid arthritis study 37 (mono; CD14+ CD16-)
Peripheral blood CD14+ CD16- monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00?19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81?2.02 mg/dl; ESR 83.67?46.21 mm/hr; DAS28-CRP 5.06?1.22; DAS28-ESR 5.92?1.50; SDAI 28.76?19.03; CDAI 25.95?18.08; HAQ-DI 1.02?0.95; TJC28 8.17?6.4; SJC28 7.50?7.66; Pain, VAS 52.67?20.20; Physician GA, VAS 46.83 ?29.30 mm; Subject GA, VAS 56.00?17.61 mm

HCC study 20 (CDX; Hep-G2; orthotopic) / HCC study 20 (PDX; orthotopic)

Relative Expression (log2-ratio):4.7345123
Number of Samples:5 / 11
Experimental HCC study 20 (CDX; Hep-G2; orthotopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) orthotopically generated in SCID mice by injecting hepatocellular carcinoma cells directly into liver parenchyma. In order to establish orthotopic model, the left lobe of liver was exposed through midline abdominal incision and cells were injected directly into liver parenchyma of mice. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; orthotopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample orthotopically generated in SCID mice by injecting hepatocellular carcinoma cells directly into liver parenchyma. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish orthotopic model, the left lobe of liver was exposed through midline abdominal incision and cells were injected directly into liver parenchyma of mice. The mice were euthanized after two weeks.

colchicine study 7 (4000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):4.3903694
Number of Samples:2 / 2
Experimental colchicine study 7 (4000uM)
Hepatocytes treated with compound: colchicine (4000uM; CHEMBL107) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.

pancreatic islet study 3 (re-differentiated; Whittier) / normal pancreatic islet sample

Relative Expression (log2-ratio):-4.3652706
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; Whittier)
Human pancreatic islets were from 2 male donors (46 and 54 years old, body mass index 21kg/m2 and 31.6kg/m2). Islets cells were expanded for 4 weeks and re-differentiated for 1 week according to Whittier protocol. Re-differentiation phase: After four passages (1 month expansion), cells were dispersed with Versene and cultured in serum-free CMRL-1066 medium supplemented with insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml). After 1 week of culture on HTB-9-coated plates, cells were harvested and forced to reaggregate overnight.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

small cell lung cancer study 4 (2. gen. PDX) / small cell lung cancer study 4 (1. gen. PDX)

Relative Expression (log2-ratio):-4.349963
Number of Samples:4 / 4
Experimental small cell lung cancer study 4 (2. gen. PDX)
Xenografts (secondary) tumor tissue samples derived from a PDX-derived cell lines. A patient derived xenograft (PDX)-derived cell lines were grown under conventional tissue culture conditions for six months and then reimplanted to generate secondary xenografts (2. gen.).
Control small cell lung cancer study 4 (1. gen. PDX)
A small cell lung cancer (SCLC) primary xenograft tumor tissue samples derived from three chemo-naive patients (LX22; LX33 and LX36; first generation-1. gen.). The discarded tissue obtained during bronchoscopy of SCLC patients was used to generate a xenograft. Aseptically resuspended tumour cells were injected s.c. in the flanks of nonobese diabetic/severe combined immunodeficient mice (NOD/SCID). The mice were sacrificed when the P0 tumors reached 1cm in diameter.